July 1, 2024

Differences in 21-Gene and PAM50 Recurrence Scores in Younger and Black Women With Breast Cancer

Puntos clave

Los puntos clave no están disponibles para este artículo en este momento.

Resumen

Genomic tests, such as the Oncotype Dx 21-gene and Prosigna risk of recurrence (ROR-P) assay, are commonly used for breast cancer prognostication. Emerging data suggest variability between assays, but this has not been compared in diverse populations.

Me gusta

Guardar

Cite This Study

Alsten et al. (Mon,) studied this question.

synapsesocial.com/papers/68e61dfeb6db6435875b0312 https://doi.org/https://doi.org/10.1200/po.24.00137

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Racial and Ethnic Disparities in Oncotype DX Test Receipt in a Statewide Population-Based Study2017 · 47 citations
2Determinants of RNA Quality from FFPE Samples2007 · 467 citations
3Breast Cancer Trends Among Black and White Women in the United States2005 · 145 citations
4Randomized Recruitment in Case-Control Studies1991 · 172 citations
5Racial differences in predictive value of the 21-gene recurrence score assay: a population-based study using the SEER database2022 · 7 citations

Me gusta

Guardar